Lutris Pharma Receives Notice of Allowance for Key U.S. Patent Application Covering Lead Compound, LUT014, a Novel B-Raf Inhibitor

/PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects,...

Related Keywords

Israel ,Noa Shelach ,Lutris Pharma ,Trademark Office ,Rx Communications ,Patent Application ,Topicalb Raf Inhibitors ,Radiation Dermatitis ,Strengthens Intellectual Property Position Until ,Chief Executive Officer ,B Raf Inhibitors ,Epidermal Growth Factor ,